These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

778 related items for PubMed ID: 18376309

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC, Holzscheiter L, Kotzsch M, Luther T, Kiechle-Bahat M, Sweep FC, Span PN, Schmitt M, Magdolen V.
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [Abstract] [Full Text] [Related]

  • 4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 5. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C, Moses EK, Quinn MA, Rice GE.
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [Abstract] [Full Text] [Related]

  • 6. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J, Mizokami Y, Takahashi K, Nakajima K, Ohtsubo T, Miura S, Narasaka T, Takeyama H, Omata T, Shimokobe K, Ito M, Takehara H, Matsuoka T.
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [Abstract] [Full Text] [Related]

  • 7. Significant overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma using real-time quantitative reverse transcription polymerase chain reaction.
    Nielsen A, Scarlett CJ, Samra JS, Gill A, Li Y, Allen BJ, Smith RC.
    J Gastroenterol Hepatol; 2005 Feb; 20(2):256-63. PubMed ID: 15683429
    [Abstract] [Full Text] [Related]

  • 8. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
    Prenzel KL, Warnecke-Eberz U, Xi H, Brabender J, Baldus SE, Bollschweiler E, Gutschow CA, Hölscher AH, Schneider PM.
    Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
    [Abstract] [Full Text] [Related]

  • 9. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A, Brun P, Sartori MT, Cortivo R, Dedominicis C, Saggiorato G, Abatangelo G, Secchi AG.
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [Abstract] [Full Text] [Related]

  • 10. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q, Liang LJ, Peng BG, Zhen YY.
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [Abstract] [Full Text] [Related]

  • 11. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
    Bhuvarahamurthy V, Schroeder J, Denkert C, Kristiansen G, Schnorr D, Loening SA, Jung K, Staack A.
    Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB, Taylor M, Grøndahl-Hansen J, Kakolyris S, Gatter KC, Harris AL.
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [Abstract] [Full Text] [Related]

  • 13. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R, Landete JM, España F, Vázquez C, Fuster C, Almenar SM, Ramón LA, Radtke KP, Estellés A.
    Thromb Res; 2007 Sep; 120(5):753-62. PubMed ID: 17258797
    [Abstract] [Full Text] [Related]

  • 14. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C, Doering DL, Goldsmith LJ, Meyer JS, Abdulhay G, Wittliff JL.
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [Abstract] [Full Text] [Related]

  • 15. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma.
    Bhuvarahamurthy V, Schroeder J, Kristiansen G, Roigas J, Denkert C, Johannsen M, Lein M, Loening SA, Schnorr D, Jung K, Staack A.
    Oncol Rep; 2005 Sep; 14(3):777-82. PubMed ID: 16077991
    [Abstract] [Full Text] [Related]

  • 16. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M, Masanobu M, Takehiko K, Shoko T, Akira F, Katsushige A, Takashi H, Yoshiyuki O, Shigeru K.
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [Abstract] [Full Text] [Related]

  • 17. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.
    Nordengren J, Pilka R, Noskova V, Ehinger A, Domanski H, Andersson C, Høyer-Hansen G, Hansson SR, Casslén B.
    Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126
    [Abstract] [Full Text] [Related]

  • 18. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A, Xue M, Jackson C, Smith RC.
    Int J Biochem Cell Biol; 2009 Sep; 41(8-9):1731-8. PubMed ID: 19433314
    [Abstract] [Full Text] [Related]

  • 19. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 20. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
    Mahanivong C, Yu J, Huang S.
    Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.